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Abstract
Aims: The quantification of protein levels in
muscle biopsies is of particular relevance in
the diagnostic process of neuromuscular
diseases, but is difficult to assess in cases of
partial protein deficiency, particularly when
information on protein localization is
required. The combination of
immunohistochemistry and western blotting is
often used in these cases, but is not always
possible if sample is scarce. We therefore
sought to develop a method to quantify
relative levels of sarcolemma-associated
proteins using digitally captured images of
immunolabelled sections of skeletal muscle.
Methods: To validate our relative
quantification method, we labelled dystrophin
and other sarcolemmal proteins in transverse
sections of muscle biopsies taken from
Duchenne Muscular Dystrophy (DMD) and
Becker Muscular Dystrophy (BMD) patients, a
manifesting carrier of DMD and normal
controls.
Results: Using this method to quantify relative
sarcolemmal protein abundance, we were
able to accurately distinguish between the
different patients on the basis of the relative
amount of dystrophin present.
Conclusions: This comparative method adds
value to techniques that are already part of
the diagnostic process and can be used with
minimal variation of the standardised
protocols, without using extra amounts of
valuable biopsy samples. Comparative
quantification of sarcolemmal proteins on
immunostained muscle sections will be of use
to establish both the abundance and
localization of the protein. Moreover, it can
be applied to assess the efficacy of
experimental therapies where only partial
restoration or upregulation of the protein,
may occur.
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Introduction
The study of proteins expressed either at the
muscle fibre plasmalemma, or in the basal
lamina extracellular matrix, is the basis for the
diagnosis of a number of muscular
dystrophies. These include DMD,
characterized by the absence of the
sarcolemmal- associated cytoskeletal protein
dystrophin, congenital muscular dystrophy
MDC1A, due to the deficiency of the
extracellular matrix protein laminin α2, and 
Ullrich CMD, due to reduced collagen VI [1].
However, in some of these conditions the
protein deficiency is subtle, and can be
difficult to evaluate. Moreover, in some
muscular dystrophies the patterns of
secondary protein changes can aid in the
diagnostic process [1]. Examples of these are
cases of utrophin upregulation in
dystrophinopathies [2]; dystrophin reduction
in some sarcoglycanopathies [3, 4]; absent
2nitric oxide synthase in DMD and some BMD
patients [5, 6]; reduced laminin α2 in alpha 
dystroglycanopathies [7, 8] or increases in
laminin α5 in MDC1A and 
dystroglycanopathies [9]. The quantitative
study of the expression of these proteins, and
their localization, is also vital for the correct
assessment of experimental strategies
designed to restore the missing protein in
adequate amount, in the correct localization
and interacting appropriately with other
proteins in order to restore muscle function.
Immunohistochemical techniques are
frequently used to study the abundance and
localization of proteins associated with these
diseases [10]. Western blot analysis is also of
use in the diagnosis of patients affected by
muscular dystrophies, offering valuable semi-
quantitative data [11]. However, this
technique requires greater amounts of sample
and volume of antibodies and it only offers
true quantitative information when studying
samples far from the low and high detection
limits [11, 12]. Furthermore, in diseases like
Ullrich congenital muscular dystrophy
(UCMD), where a reduction in collagen VI in
the basal lamina rather than the interstitial
connective tissue is a feature, reliable
quantitative information of basal lamina
protein levels is crucial [13].
In order to combine information on protein
localisation and abundance, we sought to
develop a reproducible method to be able to
quantitatively measure protein abundance in
immunohistochemical labelled skeletal
muscle. As many of the disease-relevant
proteins are currently analysed on muscle
sections using a standard diagnostic antibody
panel [1], this technique to quantify relative
sarcolemmal protein abundance could be
undertaken with minimal variation of the
standardised protocols and without the use of
extra amounts of valuable sample.
To validate this method, we compared the
amount of dystrophin in muscle samples from
a number of patients with different levels of
dystrophin expression:
a) DMD patients, in whom mutations in the
DMD gene which disrupt the reading
frame and prevent production of
functional dystrophin [12, 14].
b) Becker Muscular Dystrophy (BMD)
patients, with allelic mutations in the
DMD gene which maintain the reading
frame giving rise to shorter but semi-
functional dystrophins and a milder
phenotype [12, 15, 16]. These internally
deleted dystrophins, likely to be less
stable compared to wild type protein,
result in reduced, but variable, protein
levels in these patients.
c) Manifesting female carriers of DMD, with
a mosaic expression of dystrophin
negative and positive fibres, due to
different X-inactivation in different
myonuclei [17, 18].
d) Control individuals, with no known




Skeletal muscle biopsies were obtained with
informed consent from patients with DMD
(n=8), BMD (n=1), normal controls (n=5) and a
manifesting carrier of DMD (n=1) (Table 1). All
boys with DMD followed a typical clinical
course; the BMD patient (in frame deletion
45-47) was a mild case: currently 8 years old,
is able to walk for long distances, run and hop.
The clinical severity of the manifesting carrier
is moderate with clear symptoms mostly
related to pain and fatigability, her main
limitation being muscle cramps when walking.
Samples from the quadriceps muscle
(minimum sample size 4x3x3mm) were
obtained using a needle technique at the
Dubowitz Neuromuscular Centre in
Hammersmith Hospital, London, recently
relocated to the Institute of Child Health &
Great Ormond Street Hospital for Children,
London. Samples from the extensor digitorum
brevis (EDB) and paraspinal muscles were
obtained at the Royal National Orthopaedic
Hospital in Stanmore, UK, during foot and
scoliosis surgery. Control paraspinal samples
3were obtained from patients with adolescent
idiopathic scoliosis during their scoliosis
surgery. Ethical approval for this project was
granted by the Multi-centre Research Ethics
Committee (MREC) in UK. Muscle biopsies
were rapidly frozen in isopentane cooled in
liquid nitrogen according to standard
techniques. Unfixed frozen transverse sections
(7 μm) were incubated with primary 
antibodies for 1 hr at room temperature.
Following three washes in PBS, sections were
incubated with biotinylated secondary anti-
mouse or anti-rabbit antibodies (Amersham
UK, 1:200) for 1 hr at room temperature.
Samples were then incubated with
streptavidin conjugated to Alexa 594
(Invitrogen UK, 1:1000 for 15 min at room
temperature and washed in PBS before
mounting in Histomount (National
Diagnostics). The antibodies used were: Dys 2
(1:20) and P7 (1:1000) (against dystrophin
exons 77-79 and 57-60 respectively) (15, 16),
β-dystroglycan (BDG)(1:20), α-sarcoglycan 
(ASG) (1:50), spectrin (SP)(1:20), and utrophin
(UTR)(1:5). All primary antibodies except P7
were monoclonal and obtained from Vision
Biosystems, UK. P7 was a rabbit polyclonal
antibody produced against the same sequence
as Sherrat et al. [19].
Intensity measurements
Sections from the biopsies were
immunolabelled and evaluated using a Leica
DMR microscope interfaced to Metamorph
(Molecular Devices, US). Control muscle
sections, expressing normal levels of
dystrophin, were immunostained
simultaneously and used to set the exposure
values for the DMD samples for each of the
antibodies used except for utrophin, for which
the exposure settings were those of one of
the DMD samples. Four images of different
sectors of the section selected at random
while out of focus were focused, captured and
analysed from each the sample. From each
image, ten different regions were randomly
selected. However, if the region was in the
centre of the fibre, on an area of fibrosis, on a
neuromuscular junction or if more than one
measurement per fibre was selected, the
region was moved slightly to the nearest fibre
membrane. The measured regions included
both a portion of the cytoplasm and the
sarcolemma (Figure 1A).
The principles of this technique are the
following: when excited, fluorescent labelled
antibodies bound to the proteins release
photons that are captured by the Charge
Coupled Device (CCD), converted into
electrons. The number of electrons, which is
directly proportional to the intensity of the
fluorescence, are then mapped on to an image
in MetaMorph and presented as an intensity
value (Figure 1B and C). The dynamic range of
the camera (a 12 bit Photometrics
CoolSnapHQ2) was 0-4095 intensity units and
our measurements were taken so that pixel
saturation was avoided (all our intensity
measurements were well below the saturation
limit). Intensity measurements of these
regions were logged into a spreadsheet for
data analysis. For each antibody used, 40
different measurements from each sample
were taken.
Patient Diagnosis Biopsy
1 Control (normal dystrophin) Quadriceps
2 DMD Deleted exons 50-53 Quadriceps
3 DMD Deleted exons 46-52 Quadriceps
4 DMD Deleted exons 3-13 Quadriceps
5 DMD Deleted exon 44 Quadriceps
6 Quad DMD Deleted exons 45-52 Quadriceps
6 EDB DMD Deleted exons 45-52 EDB
7 Control (idiopathic scoliosis) Paraspinal
8 DMD Deleted exons 46-49 Quadriceps
9 BMD Deleted exons 45-47 Quadriceps
10 Manifesting Carrier Quadriceps
11 Control (idiopathic scoliosis) Paraspinal
12 Control (idiopathic scoliosis) Serratus
13 Control (idiopathic scoliosis) Paraspinal
14 Control (idiopathic scoliosis) Intercostal
15
Quad
DMD Stop mutation in exon 70 Quadriceps
15 EDB
(R)
DMD Stop mutation in exon 70 Right EDB
15 EDB
(L)
DMD Stop mutation in exon 70 Left EDB
Table 1 Diagnosis, and muscle type of the samples
used in this study.
4Data analysis
Each region where intensity values were
measured contained a portion of the
cytoplasm and of the sarcolemma, reflecting
the location of the proteins of interest. For
each region, the minimum intensity value
recorded (representative of the cytoplasm or
background intensity) was subtracted from
the maximum intensity value (which
corresponded to the sarcolemma) to correct
each measurement for background intensity.
To correct for variation of sarcolemmal
integrity between samples, we performed the
same measurements on serial sections stained
with a β-spectrin antibody. The spectrin 
intensity values obtained for the control
samples were set as the standard to calculate
normalization factors.
For each of the antibodies, the minimum
intensity value was subtracted from the
maximum, then these values (one per each of
the 40 fibres analysed) were normalized with
the β-spectrin measurements and plotted on a 
graph. Data are presented in scatter plots and
summarized as a ratio of the control.
Statistical analysis of the data was performed
using one-way analysis of the variance.
Results
Intensity measurements can distinguish
dystrophin protein levels in DMD, BMD and
manifesting carrier
We compared muscle sections taken from a
normal control, a DMD patient, a BMD patient
and a manifesting carrier, using two
dystrophin antibodies (Dys2 and P7). We also
studied in parallel the intensity of dystrophin-
associated complex proteins (ASG, BDG) and
UTR (Figure 2A). When a DMD sample was
compared with a BMD and the standard
control using Dys2 antibody, the DMD sample
showed very low dystrophin intensity relative
to the normal control (barely over the
background level), while the BMD sample
showed an intermediate intensity relative to
the control (approximately 0.5 of the control
values). When the same samples were studied
with P7, an antibody to a different region of
the dystrophin protein, the findings were
comparable: DMD showed values close to
0.15 of the control, while the BMD sample
was 0.6 (Figure 2A). In both cases, the
differences between BMD and DMD samples
were highly significant (p<0.001).
In both DMD and BMD muscles, a decrease in
the associated proteins ASG and BDG was also
detected (Figure 2A). While BDG intensity was
similarly reduced both in DMD and BMD
muscles (0.4 and 0.35 of the control) (Figure
2A), the BMD sample studied showed lower
relative intensity of ASG than the DMD sample
(0.15 and 0.4 of the control, respectively).
In cases of dystrophin deficiency, utrophin is
up-regulated at the sarcolemma [2]. Our
comparative intensity measurements
confirmed this: sections of DMD muscles
showed a marked increase in relative intensity
compared to the control; the over-expression
of utrophin was inversely correlated to the
depletion of dystrophin (Figure 2). This over-
expression was approximately five times the
control in the DMD sample (the DMD sample
was used as the reference for the capture
settings), in which dystrophin was absent, and
close to 3 times in the BMD sample. These
differences were statistically significant
(p<0.001).
The analysis of the manifesting carrier sample
revealed mean dystrophin intensity
measurements similar to those obtained from
the BMD sample (Figure 2A). However, when
studying the scatter plots for this sample, a
very clear segregation of the fibres was
evident. As sections of this sample showed a
mosaic pattern of dystrophin expression, with
some fibres staining strongly and others more
weakly (Figure 1), the study was extended to
select 100 measurements of strongly-labelling
(bright) and 100 measurements of weakly-
labelling (dim) fibres, instead of the usual
random measurements. When these
measurements were compared to control
muscle, the weakly stained fibres showed
values no significant difference to those in
DMD samples, whereas the strongly staining
fibres were not as bright as the control
(p<0.001), but showed values of similar
intensity as those observed in BMD samples
(Figure 2B).
5Figure 1 A) Example of the way regions were positioned in the image and how the intensity of those regions was
recorded. Each of the ten regions (labelled in yellow in the left image) was measured to obtain the intensity
measurements (right) used in this study. B) Transverse cryosections of quadriceps muscle biopsies,
immunostained with Dys 2 antibody showing control (normal immunostaining), DMD, showing no dystrophin,
BMD, showing decreased intensity, and a manifesting carrier, with characteristic mosaic dystrophin expression.
C) The corresponding intensities profiles of the images in B, as they are detected by the Metamorph program.
6Subtle differences in dystrophin intensity
reported by pathologists are easily identifiable
with this method.
In approximately 20% of DMD patients, traces
of dystrophin- patches of below-normal
dystrophin-positive areas visible at the
sarcolemma of muscle fibres- are present [11].
The quantification of this low level of
dystrophin expression by western blotting
would require high amounts of sample [20].
To attempt to quantify traces of dystrophin
with our method to quantify relative
sarcolemmal protein abundance, sections
from six DMD patients (Table 1) were stained
with Dys2 antibody and results compared with
the reports from the pathologist (CAS) who
had previously reported trace expression of
dystrophin in three of them. We found a
complete concordance between our
measurements and the pathologist’s reports:
those samples that showed higher relative
intensity when analysed with our method
were described in the report as showing
traces, as opposed to complete absence, of
dystrophin (Figure 3).While there were no
significant differences between the samples
containing traces (samples 3, 4 and 5), the
differences between them and those without
traces (samples 2, 6A and 6B) were highly
significant (p<0.001).
Sample variability
To evaluate how much variability there is in
the standard samples used as controls, a set
of quadriceps muscle biopsies from 4
individuals without a neuromuscular disease
were compared. While in three cases the
analysis failed to show any significant
difference between the samples analysed,
muscle from one control showed significantly
reduced dystrophin expression (p<0.01 or
p<0.05 between control 11 and controls 12
and 14 in Dys2 analysis)(Figure 4A).
To determine if samples from different
muscles of the same DMD patient contained
similar levels of dystrophin, 3 samples from
the same patient were compared (quadriceps
sample taken at the time of diagnosis, right
and left EDBs taken ten years later). All three
samples showed very limited dystrophin
intensity when analysed with both dystrophin
antibodies (0.05 of control for Dys2 and 0.15
of control for P7), a similar decrease in the
sarcolemmal associated proteins (BDG: 0.36 of
control and ASG 0.65) and over-expression of
utrophin to an equivalent level (approximately
6.5 times the intensity of the control) (Figure
4b). There was no statistically significant
difference between any of these
measurements.
7Figure 2
A) Comparative analysis of a control, DMD, BMD and a manifesting carrier muscle sample. B) The same data,
once the manifesting carrier samples had been divided into strongly and weakly-labelling fibres.
8Figure 3 A) Images from sections stained with Dys2 antibody and their corresponding intensity profiles. B)
Transcript from the pathologist reports corresponding to the samples in A and C. C) Relative intensity
measurements obtained when this group of 6 DMD samples were compared against one control.
Discussion
A range of muscular dystrophies are routinely
diagnosed by immunostaining muscle
biopsies, sometimes in combination with
western blotting analysis. Many of these
disorders, such as DMD or BMD or UCMD, are
characterised by reduced expression of
sarcolemmal proteins, which is sometimes
subtle [13]. Secondary protein changes also
often occur [1], Quantification of protein
expression from muscle biopsies is not trivial;
while western blot analysis of serial dilutions
of muscle lysate can provide semiquantitative
analysis, it requires an amount of tissue that is
not always available [20, 21].
In this study, we have compared the levels of
dystrophin expression in muscle fibres of
DMD, BMD, a manifesting carrier and patients
with normal dystrophin expression.
We first used randomly-encountered regions
of each image of immunostained muscle
transverse sections to perform the analysis.
This has the advantage of avoiding any bias
from the operator, although can obviously
miss discrete areas of relevance, e.g. clusters
of revertant fibres in DMD [22, 23], or the
mosaic dystrophin expression observed in
DMD manifesting carriers [17, 24]. The mean
relative dystrophin intensity of randomly-
encountered fibres in a manifesting carrier
was similar to a BMD patient (Figure 2A), but
when the intensity of strongly and weakly
labelled fibres was measured separately, the
mosaic pattern of dystrophin expression
characteristic of a manifesting carrier was
readily quantifiable (Figure 2B). Similarly,
when randomly analysing fibres from sections
containing revertant fibres, either an
increased average intensity, or higher
standard errors of the mean was seen,
implying that revertant fibre(s) had been
included in the analysis (e.g. sample 5 in
Figure 3).
As with any semi-quantitative technique,
reliable internal controls and standards are
vital. We chose β-spectrin as our internal 
control, to account for differences in the
integrity of the fibres. We have previously
9Figure 4 A) Comparative analysis of four different controls (scoliosis patients). B) Three samples from three
different muscles of the same patient were analysed and compared with a control.
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shown that spectrin is an ideal marker of
sarcolemmal integrity as it is not a protein of
the dystrophin complex [25] and is not
affected by dystrophin deficiency, except on
necrotic and regenerating fibres [26]. All
measurements were normalised with their
corresponding serial section labelled for β-
spectrin. All measurements were expressed
relative to the normal dystrophin in standard
controls in each particular experiment and
should not be considered absolute values, as
we confirmed that there is a certain degree of
variability even between controls (Figure 4).
We believe that this technique will be an
additional useful tool to the techniques
currently in place in diagnosis of
neuromuscular diseases in which the study of
localization and amount of protein is
paramount. We also propose this technique
as an objective method to quantify protein
expression when assessing efficacy of
experimental therapies aimed at restoring
protein expression such as in the recent trials
of antisense oligonucleotides in DMD [27, 28].
Acknowledgements
The Authors wish to thank the Department of
Health (UK) for the funding of this study, and
the Muscular Dystrophy Campaign Centre
grant. The Biobank of the MRC Neuromuscular
translational research centre is also gratefully
acknowledged. JEM was funded by an MRC
collaborative career development fellowship
in stem cell research and is currently funded
by a Wellcome Trust University award. SB is
funded by the AFM and MDA. The authors
also wish to thank Mr David Hunt, Mr Jan
Lehowsky, Dr Geraldine Edge, Jihee Kim and
Darren Chambers for their technical expertise.
Author Disclosure Statement
No competing financial interests exist.
References
1 Dubowitz V, Sewry C. Muscle Biopsy: A
practical approach. Third Edition ed: SAUNDERS Elsevier.
2007
2 Karpati G, Carpenter S, Morris GE, Davies KE,
Guerin C, Holland P. Localization and quantitation of the
chromosome 6-encoded dystrophin-related protein in
normal and pathological human muscle. J Neuropathol
Exp Neurol 1993 Mar; 52: 119-28
3 Jones KJ, Kim SS, North KN. Abnormalities of
dystrophin, the sarcoglycans, and laminin alpha2 in the
muscular dystrophies. J Med Genet 1998 May; 35: 379-86
4 Vainzof M, Passos-Bueno MR, Canovas M,
Moreira ES, Pavanello RC, Marie SK, Anderson LV,
Bonnemann CG, McNally EM, Nigro V, Kunkel LM, Zatz M.
The sarcoglycan complex in the six autosomal recessive
limb-girdle muscular dystrophies. Hum Mol Genet 1996
Dec; 5: 1963-9
5 Brenman JE, Chao DS, Xia H, Aldape K, Bredt
DS. Nitric oxide synthase complexed with dystrophin and
absent from skeletal muscle sarcolemma in Duchenne
muscular dystrophy. Cell 1995 Sep 8; 82: 743-52
6 Torelli S, Brown SC, Jimenez-Mallebrera C,
Feng L, Muntoni F, Sewry CA. Absence of neuronal nitric
oxide synthase (nNOS) as a pathological marker for the
diagnosis of Becker muscular dystrophy with rod domain
deletions. Neuropathol Appl Neurobiol 2004 Oct; 30: 540-
5
7 Michele DE, Barresi R, Kanagawa M, Saito F,
Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H,
Straub V, Mathews KD, Moore SA, Campbell KP. Post-
translational disruption of dystroglycan-ligand
interactions in congenital muscular dystrophies. Nature
2002 Jul 25; 418: 417-22
8 Brockington M, Blake DJ, Prandini P, Brown SC,
Torelli S, Benson MA, Ponting CP, Estournet B, Romero
NB, Mercuri E, Voit T, Sewry CA, Guicheney P, Muntoni F.
Mutations in the fukutin-related protein gene (FKRP)
cause a form of congenital muscular dystrophy with
secondary laminin alpha2 deficiency and abnormal
glycosylation of alpha-dystroglycan. Am J Hum Genet 2001
Dec; 69: 1198-209
9 Sewry CA, Philpot J, Mahony D, Wilson LA,
Muntoni F, Dubowitz V. Expression of laminin subunits in
congenital muscular dystrophy. Neuromuscul Disord 1995
Jul; 5: 307-16
10 Muntoni F. Is a muscle biopsy in Duchenne
dystrophy really necessary? Neurology 2001 Aug 28; 57:
574-5
11 Nicholson LV, Davison K, Falkous G, Harwood
C, O'Donnell E, Slater CR, Harris JB. Dystrophin in skeletal
muscle. I. Western blot analysis using a monoclonal
antibody. J Neurol Sci 1989 Dec; 94: 125-36
12 Hoffman EP, Brown RH, Jr., Kunkel LM.
Dystrophin: the protein product of the Duchenne
muscular dystrophy locus. Cell 1987 Dec 24; 51: 919-28
13 Ishikawa H, Sugie K, Murayama K, Awaya A,
Suzuki Y, Noguchi S, Hayashi YK, Nonaka I, Nishino I.
Ullrich disease due to deficiency of collagen VI in the
sarcolemma. Neurology 2004 Feb 24; 62: 620-3
14 Muntoni F, Torelli S, Ferlini A. Dystrophin and
mutations: one gene, several proteins, multiple
phenotypes. Lancet Neurol 2003 Dec; 2: 731-40
15 Koenig M, Beggs AH, Moyer M, Scherpf S,
Heindrich K, Bettecken T, Meng G, Muller CR, Lindlof M,
Kaariainen H, et al. The molecular basis for Duchenne
versus Becker muscular dystrophy: correlation of severity
with type of deletion. Am J Hum Genet 1989 Oct; 45: 498-
506
16 Monaco AP, Bertelson CJ, Liechti-Gallati S,
Moser H, Kunkel LM. An explanation for the phenotypic
11
differences between patients bearing partial deletions of
the DMD locus. Genomics 1988 Jan; 2: 90-5
17 Hoffman EP, Arahata K, Minetti C, Bonilla E,
Rowland LP. Dystrophinopathy in isolated cases of
myopathy in females. Neurology 1992 May; 42: 967-75
18 Bonilla E, Schmidt B, Samitt CE, Miranda AF,
Hays AP, de Oliveira AB, Chang HW, Servidei S, Ricci E,
Younger DS, et al. Normal and dystrophin-deficient
muscle fibers in carriers of the gene for Duchenne
muscular dystrophy. Am J Pathol 1988 Dec; 133: 440-5
19 Sherratt TG, Vulliamy T, Strong PN.
Evolutionary conservation of the dystrophin central rod
domain. Biochem J 1992 Nov 1; 287 ( Pt 3): 755-9
20 Anderson LV, Davison K. Multiplex Western
blotting system for the analysis of muscular dystrophy
proteins. Am J Pathol 1999 Apr; 154: 1017-22
21 Hoffman EP, Fischbeck KH, Brown RH, Johnson
M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M,
Specht L, et al. Characterization of dystrophin in muscle-
biopsy specimens from patients with Duchenne's or
Becker's muscular dystrophy. N Engl J Med 1988 May 26;
318: 1363-8
22 Hoffman EP, Morgan JE, Watkins SC, Partridge
TA. Somatic reversion/suppression of the mouse mdx
phenotype in vivo. J Neurol Sci 1990 Oct; 99: 9-25
23 Nicholson LV, Davison K, Johnson MA, Slater
CR, Young C, Bhattacharya S, Gardner-Medwin D, Harris
JB. Dystrophin in skeletal muscle. II. Immunoreactivity in
patients with Xp21 muscular dystrophy. J Neurol Sci 1989
Dec; 94: 137-46
24 Bonilla E, Samitt CE, Miranda AF, Hays AP,
Salviati G, DiMauro S, Kunkel LM, Hoffman EP, Rowland
LP. Duchenne muscular dystrophy: deficiency of
dystrophin at the muscle cell surface. Cell 1988 Aug 12;
54: 447-52
25 Kobayashi T Fau - Ohno S, Ohno S Fau - Park-
Matsumoto YC, Park-Matsumoto Yc Fau - Kameda N,
Kameda N Fau - Baba T, Baba T. Developmental studies of
dystrophin and other cytoskeletal proteins in cultured
muscle cells. 1995:
26 Sewry CA. Immunocytochemical analysis of
human muscular dystrophy. Microsc Res Tech 2000 Feb 1-
15; 48: 142-54
27 van Deutekom JC, Janson AA, Ginjaar IB,
Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den
Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de
Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ,
Verschuuren JJ, van Ommen GJ. Local dystrophin
restoration with antisense oligonucleotide PRO051. N
Engl J Med 2007 Dec 27; 357: 2677-86
28 Kinali M, Arechavala-Gomeza V, Feng L, Cirak S,
Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S,
Nihoyannopoulos P, Garralda ME, Rutherford M,
McCulley C, Popplewell L, Graham IR, Dickson G, Wood
MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry
C, Morgan JE, Muntoni F. Local restoration of dystrophin
expression with the morpholino oligomer AVI-4658 in
Duchenne muscular dystrophy: a single-blind, placebo-
controlled, dose-escalation, proof-of-concept study.
Lancet Neurol 2009 Aug 25:
